Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV

 Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales                     Force for BELVIQ® (lorcaserin HCl) CIV  -- Sales Force Increased to Approximately 600 Sales Specialists --  PR Newswire  SAN DIEGO, July 10, 2014  SAN DIEGO, July 10, 2014 /PRNewswire/ --Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in the United States.  "We are enthusiastic about the commercial ramp-up for BELVIQ with this further increase in the sales force," said Jack Lief, Arena's President and Chief Executive Officer. "This involves a large-scale deployment of additional sales representatives who will increase Eisai's ability to educate physicians. We support the approach and believe that it will help produce greater results."  BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m^2 or greater (obese), or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related, comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes). It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, and the effect of BELVIQ on cardiovascular morbidity and mortality has not been established.  Eisai is responsible for the marketing and distribution of BELVIQ in the United States under its agreement with Arena.  About BELVIQ® (lorcaserin HCl) CIV  BELVIQ is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. The exact mechanism of action of BELVIQ is not known.  BELVIQ is approved by the US Food and Drug Administration. Eisai markets and distributes BELVIQ in the United States, and Arena manufactures and supplies the finished commercial product from its facility in Switzerland. Eisai and Arena's marketing and supply agreement for BELVIQ covers most territories worldwide. For more information about BELVIQ, click here for the full US FDA-approved Product Information or visit www.BELVIQ.com.  IMPORTANT SAFETY INFORMATION  Contraindication    oBELVIQ should not be taken during pregnancy or by women who are planning     to become pregnant.  Warnings and Precautions    oBELVIQ is a serotonergic drug. The development of potentially     life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome     (NMS)-like reactions have been reported during use of serotonergic drugs,     including, but not limited to, selective serotonin-norepinephrine reuptake     inhibitors, and selective serotonin reuptake inhibitors, tricyclic     antidepressants, bupropion, triptans, dietary supplements such as St.     John's Wort and tryptophan, drugs that impair metabolism of serotonin     (including monoamine oxidase inhibitors), dextromethorphan, lithium,     tramadol, antipsychotics or other dopamine antagonists, particularly when     used in combination. Patients should be monitored for the emergence of     serotonin syndrome symptoms or NMS-like reactions, including agitation,     hallucinations, coma, tachycardia, labile blood pressure, hyperthermia,     hyperreflexia, incoordination, nausea, vomiting, diarrhea, and muscle     rigidity. Treatment with BELVIQ and any concomitant serotonergic or     antidopaminergic agents should be discontinued immediately if the above     events occur, and supportive symptomatic treatment should be initiated.   oPatients should not take BELVIQ in combination with drugs that have been     associated with valvular heart disease (e.g., cabergoline). In clinical     trials, 2.4% of patients taking BELVIQ and 2.0% of patients taking placebo     developed valvular regurgitation: none of these patients was symptomatic.     BELVIQ should be used with caution in patients with congestive heart     failure (CHF). Patients who develop signs and symptoms of valvular heart     disease, including dyspnea, dependent edema, CHF, or a new cardiac murmur,     should be evaluated and discontinuation of BELVIQ should be considered.   oImpairment in attention, memory, somnolence, confusion, and fatigue, have     been reported in patients taking BELVIQ. Patients should not drive a car     or operate heavy machinery until they know how BELVIQ affects them.   oThe recommended dose of 10 mg twice daily should not be exceeded, as     higher doses may cause euphoria, hallucination, and dissociation. Monitor     patients for the development or worsening of depression, suicidal thoughts     or behaviors, and/or any changes in mood. Discontinue BELVIQ in patients     who develop suicidal thoughts or behaviors.   oWeight loss may increase the risk of hypoglycemia in patients with type 2     diabetes mellitus who are being treated with antidiabetic medications, so     measurement of blood sugar levels before and during treatment with BELVIQ     is recommended. Decreases in doses of antidiabetic medications or changes     in medication regimen should be considered.   oMen who experience priapism should immediately discontinue BELVIQ and seek     emergency medical attention. BELVIQ should be used with caution with     erectile dysfunction medications. BELVIQ should be used with caution in     men who have conditions that might predispose them to priapism (e.g.,     sickle cell anemia, multiple myeloma, or leukemia), or in men with     anatomical deformation of the penis (e.g., angulation, cavernosal     fibrosis, or Peyronie's disease).   oBecause BELVIQ may cause a slow heartbeat, it should be used with caution     in patients with a history of bradycardia or heart block greater than     first degree.   oConsider monitoring for CBC changes, prolactin excess, and pulmonary     hypertension.  Most Common Adverse Reactions in Clinical Trials    oIn patients without diabetes: headache (17%), dizziness (9%), fatigue     (7%), nausea (8%), dry mouth (5%), and constipation (6%).   oIn patients with diabetes: hypoglycemia (29%), headache (15%), back pain     (12%), cough (8%), and fatigue (7%).  Nursing Mothers    oBELVIQ should not be taken by women who are nursing.  BELVIQ is a federally controlled substance (CIV) because it may be abused or lead to dependence.  For more information about BELVIQ, click here for the full US FDA-approved Product Information or visit www.BELVIQ.com.  About Arena Pharmaceuticals  Arena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's internally discovered drug, BELVIQ® (lorcaserin HCl), is approved in the United States, and Arena is focused on discovering, developing and commercializing additional drugs to address unmet medical needs.Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.  Arena Pharmaceuticals® and Arena®are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.  Forward-Looking Statements  Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication, use, safety, efficacy, mechanism of action, commercialization and potential of BELVIQ or lorcaserin; the commercial ramp-up for BELVIQ; the sales force for BELVIQ, including the deployment of additional representatives, and related results and other expectations; Eisai's physician reach and education; embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.  Contact:Arena Pharmaceuticals, Inc.         Media Contact: Russo Partners Craig Audet, Senior Vice President,          David Schull, President Operations and Head of Global Regulatory     david.schull@russopartnersllc.com Affairs caudet@arenapharm.com                        858.717.2310 858.453.7200, ext. 1612 www.arenapharm.com  SOURCE Arena Pharmaceuticals, Inc.  Website: http://www.arenapharm.com  
Press spacebar to pause and continue. Press esc to stop.